Knee Osteoarthritis (OA) Project Treatment Versus Conventional Physical Therapy in the Treatment of Knee OA Patients
Launched by MEIR MEDICAL CENTER · Dec 10, 2011
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
This research is divided into o Intervention and control groups. Research Population is 60 Patients (30 patients to each arm), aged 60 and above suffering from OA of the knees and admitted to physical therapy .Intervention group patients were treated by the concept of "Knee Osteoarthritis Project". This was first applied in middle of 2010 and its effectiveness was never tested.
The main idea was to make patients more active, to encourage them to do exercise at home, increase their motivation and self efficacy. In addition, patients received prescription for TENS device (Transcutaneous elec...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 60+ years old independent men and women,who suffer from OA in the knee and was referred to Physiotherapy.
- • ability to write and read properly in Hebrew
- Exclusion Criteria:
- • OA secondary to systematic disease (Rheumatoid arthritis)
- • steroids injections to the knee in the past 3 months.
- • orthopaedic surgery to lower limbs.
- • neurological deficit.
- • symptomatic OA in the hip or ankle
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Yair Barzilai, M.D.
Principal Investigator
Clalit health service, Israel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials